Chardan Capital Maintains Buy on ProQR Therapeutics, Maintains $2.5 Price Target
Benzinga Newsdesk 2 years ago
NewsPrice TargetAnalyst Ratings
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $2.5 price target.
Chardan Capital analyst Keay Nakae maintains ProQR Therapeutics (NASDAQ:PRQR) with a Buy and maintains $2.5 price target.